AbbVie Says Experimental Drug Shows Higher Crohn's Remission Rates Than Rivals in Phase 2a Study

06:05 AM EDT, 10/19/2026 (MT Newswires) -- AbbVie (ABBV) said Monday its experimental drug ABBV-466 led to more patients with Crohn's disease reaching endoscopic remission at week 12 than either of two rival treatments in a phase 2a study. At week 12, 30.2% of patients on ABBV-466 reached endoscopic remission compared with 21.3% on risankizumab and 18% on trosunilimab, and the gap widened at week 24 to 40.5% against 22.4% and 20%, respectively. The trial enrolled 300 patients with moderate to severe Crohn's disease, 75% of whom had already failed at least one advanced treatment, AbbVie said. Serious adverse events occurred in 10.4% of patients on the drug, compared with 9.6% and 9% on the two rival drugs being compared, and lab analyses pointed to repair of the bowel lining by week 12, it said.